Myricx Bio is a Biotech company based in London, UK. It has raised $114M in total funding. Latest round: Series A.
Myricx Bio funding overview
Myricx Bio is a Biotech company based in London, UK. Myricx Bio has raised $114M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in July 2024. The round record for Myricx Bio runs through 2024; nothing later has been disclosed. Investors on record include Novo Holdings, Abingworth, Brandon Capital, Sofinnova Partners, British Patient Capital, Cancer Research Horizons and 1 others. 7 distinct backers are named across the disclosed rounds.
Myricx Bio at a glance
Total raised
$114M
Latest round
Series A
Latest round date
July 2024
Industry
Biotech
Headquarters
London, UK
Notable investors
Novo Holdings, Abingworth, Brandon Capital, Sofinnova Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly and Company
Frequently asked about Myricx Bio funding
How much has Myricx Bio raised?
Myricx Bio has raised $114M in total disclosed funding across the rounds on record.
Who has invested in Myricx Bio?
Novo Holdings, Abingworth, Brandon Capital, Sofinnova Partners, British Patient Capital, Cancer Research Horizons are named among the investors backing Myricx Bio.
What was the latest Myricx Bio funding round?
The most recent disclosed round is a Series A, announced in July 2024.
Where is Myricx Bio based?
Myricx Bio is based in London, UK.
What sector does Myricx Bio operate in?
Myricx Bio is tracked under Biotech from London, UK, with $114M in disclosed funding.
When did Myricx Bio last raise?
The last disclosed Myricx Bio round closed in July 2024 at Series A.
We update the Myricx Bio record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related Biotech companies in London and their backers are listed below.
